Shares of WAVE Life Sciences WVE moved higher by 1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 5.74% over the past year to ($1.15), which missed the estimate of ($0.97).
Revenue of $3,027,000 declined by 60.32% year over year, which missed the estimate of $5,650,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
WAVE Life Sciences hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/tp8dtbav
Recent Stock Performance
52-week high: $39.98
Company's 52-week low was at $6.61
Price action over last quarter: down 9.49%
Company Profile
WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
